Galectin Therapeutics (GALT) Assets Average (2011 - 2026)
Galectin Therapeutics' quarterly Assets Average came in at $17.6 million in Q1 2026, up 30.6% year-on-year from $13.5 million in Q1 2025, and up 8.93% quarter-over-quarter from $16.2 million in Q4 2025.
Galectin Therapeutics has reported Assets Average for 16 years, with the latest figure at $17.6 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 30.6% year-over-year to $17.6 million; the trailing twelve-month figure through Mar 2026 stood at $17.6 million (up 30.6% YoY), and the FY2025 full-year result was $18.5 million, down 18.97% from the prior year.
- Assets Average for Q1 2026 stood at $17.6 million, up from $16.2 million in the prior quarter.
- The five-year high for Assets Average was $37.7 million in Q1 2022, with the low at $12.6 million in Q2 2025.
- Average Assets Average over 5 years is $22.1 million, with a median of $21.1 million recorded in 2023.
- Year-over-year, Assets Average surged 43.71% in 2022 and sank 53.07% in 2025.
- Tracing GALT's Assets Average over 5 years: stood at $19.6 million in 2022, then gained by 28.48% to $25.2 million in 2023, then decreased by 7.74% to $23.2 million in 2024, then plunged by 30.28% to $16.2 million in 2025, then gained by 8.93% to $17.6 million in 2026.
- The last three Assets Average figures came in at $17.6 million (Q1 2026), $16.2 million (Q4 2025), and $14.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 17.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.65 Mn |
| Dec 31, 2025 | 16.20 Mn |
| Sep 30, 2025 | 14.23 Mn |
| Jun 30, 2025 | 12.57 Mn |
| Mar 31, 2025 | 13.51 Mn |
| Dec 31, 2024 | 23.23 Mn |
| Sep 30, 2024 | 28.31 Mn |
| Jun 30, 2024 | 26.77 Mn |
| Mar 31, 2024 | 27.05 Mn |
| Dec 31, 2023 | 25.18 Mn |
| Sep 30, 2023 | 21.12 Mn |
| Jun 30, 2023 | 20.15 Mn |
| Mar 31, 2023 | 20.76 Mn |
| Dec 31, 2022 | 19.60 Mn |
| Sep 30, 2022 | 21.90 Mn |
| Jun 30, 2022 | 29.75 Mn |
| Mar 31, 2022 | 37.72 Mn |
| Dec 31, 2021 | 39.93 Mn |
| Sep 30, 2021 | 35.72 Mn |
| Jun 30, 2021 | 28.15 Mn |
| Mar 31, 2021 | 26.25 Mn |
| Dec 31, 2020 | 31.82 Mn |
| Sep 30, 2020 | 37.68 Mn |
| Jun 30, 2020 | 42.71 Mn |
| Mar 31, 2020 | 46.29 Mn |
| Dec 31, 2019 | 49.61 Mn |
| Sep 30, 2019 | 51.89 Mn |
| Jun 30, 2019 | 30.42 Mn |
| Mar 31, 2019 | 8.42 Mn |
| Dec 31, 2018 | 9.81 Mn |
| Sep 30, 2018 | 10.91 Mn |
| Jun 30, 2018 | 8.07 Mn |
| Mar 31, 2018 | 4.55 Mn |
| Dec 31, 2017 | 5.59 Mn |
| Sep 30, 2017 | 8.17 Mn |
| Jun 30, 2017 | 11.66 Mn |
| Mar 31, 2017 | 14.90 Mn |
| Dec 31, 2016 | 15.96 Mn |
| Sep 30, 2016 | 17.18 Mn |
| Jun 30, 2016 | 20.52 Mn |
| Mar 31, 2016 | 24.60 Mn |
| Dec 31, 2015 | 23.96 Mn |
| Sep 30, 2015 | 24.10 Mn |
| Jun 30, 2015 | 28.33 Mn |
| Mar 31, 2015 | 29.83 Mn |
| Dec 31, 2014 | 30.50 Mn |
| Sep 30, 2014 | 32.96 Mn |
| Jun 30, 2014 | 35.75 Mn |
| Mar 31, 2014 | 23.81 Mn |
| Dec 31, 2013 | 10.25 Mn |
| Sep 30, 2013 | 7.50 Mn |
| Jun 30, 2013 | 6.21 Mn |
| Mar 31, 2013 | 8.38 Mn |
| Dec 31, 2012 | 10.38 Mn |
| Sep 30, 2012 | 12.26 Mn |
| Jun 30, 2012 | 14.43 Mn |
| Mar 31, 2012 | 11.08 Mn |
| Dec 31, 2011 | 7.36 Mn |
| Sep 30, 2011 | 8.13 Mn |